Linezolid treatment of glycopeptide-resistant Enterococcus faecium in very low birth weight premature neonates

International Journal of Antimicrobial Agents

Volumn 27, Issue 3, 2006, Pages 256-258

  Hoehn, Rene ^a   Groll, Andreas H ^b   Schaefer, Volker ^a   Bauer, Karl ^a   Schloesser, Rolf L ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Enterococcus; Linezolid; Neonates; Pharmacokinetics

Indexed keywords

AMIKACIN; AMPICILLIN; CEFOTAXIME; CEFTAZIDIME; DOXYCYCLINE; ERYTHROMYCIN; FLUCONAZOLE; GENTAMICIN; GLYCOPEPTIDE; IMIPENEM; LINEZOLID; MEROPENEM; OXAZOLIDINONE DERIVATIVE; PSEUDOMONIC ACID; QUINUPRISTIN; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; ARTIFICIAL VENTILATION; BLOOD TOXICITY; CASE REPORT; CONVALESCENCE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENTEROCOCCAL INFECTION; ENTEROCOCCUS FAECIUM; FEMALE; HOSPITAL INFECTION; HUMAN; HYPOTENSION; INFANT; INJECTION SITE REACTION; INTUBATION; KIDNEY FAILURE; PATENT DUCTUS ARTERIOSUS; PNEUMONIA; PREMATURITY; PRIORITY JOURNAL; RESPIRATORY DISTRESS; SEPSIS; TREATMENT OUTCOME; VERY LOW BIRTH WEIGHT;

ACETAMIDES; DRUG RESISTANCE, BACTERIAL; ENTEROCOCCUS FAECIUM; FEMALE; GLYCOPEPTIDES; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; INFANT, NEWBORN; INFANT, VERY LOW BIRTH WEIGHT; MALE; OXAZOLIDINONES; PREMATURE BIRTH; SAFETY;

EID: 32644474373     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2005.11.006     Document Type: Article

References (23)

1. P.K. Linden Treatment options for vancomycin-resistant enterococcal infections Drugs 62 2002 425 441
2. C.A. Kauffman Therapeutic and preventative options for the management of vancomycin-resistant enterococcal infections J Antimicrob Chemother 51 Suppl. 3 2003 iii23 iii30
3. C.A. DiazGranados, and J.A. Jernigan Impact of vancomycin resistance on mortality among patients with neutropenia and enterococcal bloodstream infection J Infect Dis 191 2005 588 595
4. R.N. Jones, D.M. Johnson, and M.E. Erwin In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones Antimicrob Agents Chemother 40 1996 720 726
5. R. Norrby Linezolid - a review of the first oxazolidinone Expert Opin Pharmacother 2 2001 293 302
6. A. Marchese, and G.C. Schito The oxazolidinones as a new family of antimicrobial agents Clin Microbiol Infect 7 Suppl. 4 2001 66 74
7. T.Q. Tan Update on the use of linezolid: a pediatric perspective Pediatr Infect Dis J 23 2004 955 956
8. N.G. Tornieporth, R.B. Roberts, J. John, A. Hafner, and L.W. Riley Risk factors associated with vancomycin-resistant Enterococcus faecium infection or colonization in 145 matched case patients and control patients Clin Infect Dis 23 1996 767 772
9. D.F. McNeeley, A.E. Brown, G.J. Noel, M. Chung, and H. De Lencastre An investigation of vancomycin-resistant Enterococcus faecium within the pediatric service of a large urban medical center Pediatr Infect Dis J 17 1998 184 188
10. H.K. Lee, W.G. Lee, and S.R. Cho Clinical and molecular biological analysis of a nosocomial outbreak of vancomycin-resistant enterococci in a neonatal intensive care unit Acta Paediatr 88 1999 651 654
11. M.E. Rupp, N. Marion, and P.D. Fey Outbreak of vancomycin-resistant Enterococcus faecium in a neonatal intensive care unit Infect Control Hosp Epidemiol 22 2001 301 303
12. P.L. Graham, K. Ampofo, and L. Saiman Linezolid treatment of vancomycin-resistant Enterococcus faecium ventriculitis Pediatr Infect Dis J 21 2002 798 800
13. J.Y. Ang, J.L. Lua, D.R. Turner, and B.I. Asmar Vancomycin-resistant Enterococcus faecium endocarditis in a premature infant successfully treated with linezolid Pediatric Infect Dis J 22 2003 1101 1103
14. G.L. Kearns, G.L. Jungbluth, and S.M. Abdel-Rahman Impact of ontogeny on linezolid disposition in neonates and infants Clin Pharmacol Ther 74 2003 413 422
15. J.G. Deville, S. Adler, and P.H. Azimi Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates Pediatr Infect Dis J 22 9 Suppl. 2003 S158 S163
16. U. Klingkowski, R.G. Huth, P. Habermehl, and M. Knuf Linezolid in two premature babies with necrotizing enterocolitis and infection with vancomycin-resistant enterococcus Klin Padiatr 216 2004 21 23
17. Kaplan SL, Deville JG, Yogev R, et al.; Linezolid Pediatric Study Group. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. Pediatr Infect Dis J 2003;22: 677-86.
18. L. Saiman, J. Goldfarb, and S. Kaplan Safety and tolerability of linezolid in children Pediatr Infect Dis J 22 9 Suppl. 2003 S193 S200
19. D. Kaufman, and K.D. Fairchild Clinical microbiology of bacterial and fungal sepsis in very-low-birth-weight infants Clin Microbiol Rev 17 2004 638 680
20. D. Andes, M.L. van Ogtrop, J. Peng, and W.A. Craig In vivo pharmacodynamics of a new oxazolidinone (linezolid) Antimicrob Agents Chemother 46 2002 3484 3489
21. M.J. Gentry-Nielsen, K.M. Olsen, and L.C. Preheim Pharmacodynamic activity and efficacy of linezolid in a rat model of pneumococcal pneumonia Antimicrob Agents Chemother 46 2002 1345 1351
22. G.L. Jungbluth, I.R. Welshman, and N.K. Hopkins Linezolid pharmacokinetics in pediatric patients: an overview Pediatr Infect Dis J 22 9 Suppl. 2003 S153 S157
23. G.L. Kearns, S.M. Abdel-Rahman, and J.L. Blumer Single dose pharmacokinetics of linezolid in infants and children Pediatr Infect Dis J 19 2000 1178 1184